Ann: Starpharma signs new DEP partnership with Chase Sun, page-15

Started Googling and found this about our new [partner in the China Daily

Tianjin honors contributors to anti-virus fight

An excerpt:
"Yao Xiaoqing, president of Tianjin Chase Sun Pharmaceutical Co, the producer of the Xuebijing injection, one of the three traditional Chinese medicines pinpointed by government authorities to treat the coronavirus pneumonias, said it "has undergone 10 years of difficult component-based studies in line with rigorous Western medicine research standards, and convinced Western counterparts by its effects and results".

http://www.chinadaily.com.cn/a/202004/23/WS5ea15223a3105d50a3d1861d.html

and this study

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347326/

The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2

Is it possible Starpharma may attempt to "enhance its performance and expand its therapeutic utility" ??